Literature DB >> 22484078

γ knife surgery versus reoperation for recurrent glioblastoma multiforme.

Bente Sandvei Skeie1, Per Øyvind Enger, Jan Brøgger, Jeremy Christopher Ganz, Frits Thorsen, Jan Ingeman Heggdal, Paal-Henning Pedersen.   

Abstract

BACKGROUND: The optimal management of patients with recurrent glioblastoma multiforme (GBM) is a subject of controversy. These patients may be candidates for both reoperation and/or gamma knife surgery (GKS). Few studies have addressed the role of GKS for relapsing gliomas, and the results have not been compared with reoperation. To validate the efficacy and safety of GKS, we compared the survival and complication rates of GKS and reoperation for recurrent GBMs.
METHODS: This study retrospectively reviewed 77 consecutive patients with histopathologically confirmed GBMs retreated for recurrent GBM between 1996 and 2007. Thirty-two patients underwent GKS, 26 reoperation and 19 both procedures.
RESULTS: The median time from the second intervention to tumor progression was longer after GKS than after resection, P = 0.009. Median survival after retreatment was 12 months for the 51 patients receiving GKS compared with 6 months for reoperation only (P = 0.001, hazard ratio [HR] 2.4), and 19 months versus 16 months from the time of primary diagnosis (P = 0.021, HR 1.8). A multivariate analysis adjusted for possible confounding factors (tumor volume, recursive partitioning analysis class, neurological deficits, time to recurrence, adjuvant therapy, and tumor location) showed significantly longer survival for patients treated with GKS, both from retreatment (P = 0.013, HR 4.1) and from primary diagnosis (P = 0.002, HR 5.8). The adjusted results were still significant after separate analysis according to tumor volume <5 mL, 5 to 20 mL, and >20 mL. The complications rate was 9.8% after GKS and 25.2% after reoperation.
CONCLUSIONS: GKS may be an alternative to open surgery for small GBMs at the time of recurrences, with a significantly lower complication rate and a possible survival benefit compared with reoperation.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22484078     DOI: 10.1016/j.wneu.2012.03.024

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  30 in total

1.  Re-resection for recurrent high-grade glioma in the setting of re-irradiation: more is not always better.

Authors:  Joshua D Palmer; Joshua Siglin; Kosj Yamoah; Tu Dan; Colin E Champ; Voichita Bar-Ad; Maria Werner-Wasik; James J Evans; Lyndon Kim; Jon Glass; Christopher Farrell; David W Andrews; Wenyin Shi
Journal:  J Neurooncol       Date:  2015-05-30       Impact factor: 4.130

Review 2.  Treatment options for recurrent high-grade gliomas.

Authors:  Harjus S Birk; Seunggu J Han; Nicholas A Butowski
Journal:  CNS Oncol       Date:  2016-12-21

3.  MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma.

Authors:  Byung Sup Kim; Doo-Sik Kong; Ho Jun Seol; Do-Hyun Nam; Jung-Il Lee
Journal:  J Neurooncol       Date:  2017-05-23       Impact factor: 4.130

4.  Outcomes after second surgery for recurrent glioblastoma: a retrospective case-control study.

Authors:  Alysson Wann; Patrick A Tully; Elizabeth H Barnes; Zarnie Lwin; Rosalind Jeffree; Katharine J Drummond; Hui Gan; Mustafa Khasraw
Journal:  J Neurooncol       Date:  2018-01-02       Impact factor: 4.130

5.  Assessing the efficacy of repeat resections in recurrent glioblastoma: a systematic review.

Authors:  David Botros; Hayden Dux; Carrie Price; Adham M Khalafallah; Debraj Mukherjee
Journal:  Neurosurg Rev       Date:  2020-06-13       Impact factor: 3.042

Review 6.  External beam re-irradiation, combination chemoradiotherapy, and particle therapy for the treatment of recurrent glioblastoma.

Authors:  Neil K Taunk; Fabio Y Moraes; Freddy E Escorcia; Lucas Castro Mendez; Kathryn Beal; Gustavo N Marta
Journal:  Expert Rev Anticancer Ther       Date:  2016-02-09       Impact factor: 4.512

7.  Re-irradiation for recurrent glioblastoma (GBM): a systematic review and meta-analysis.

Authors:  Farasat Kazmi; Yu Yang Soon; Yiat Horng Leong; Wee Yao Koh; Balamurugan Vellayappan
Journal:  J Neurooncol       Date:  2018-12-06       Impact factor: 4.130

8.  Drug repurposing: sulfasalazine sensitizes gliomas to gamma knife radiosurgery by blocking cystine uptake through system Xc-, leading to glutathione depletion.

Authors:  L Sleire; B S Skeie; I A Netland; H E Førde; E Dodoo; F Selheim; L Leiss; J I Heggdal; P-H Pedersen; J Wang; P Ø Enger
Journal:  Oncogene       Date:  2015-03-23       Impact factor: 9.867

Review 9.  Recurrent malignant gliomas.

Authors:  John P Kirkpatrick; John H Sampson
Journal:  Semin Radiat Oncol       Date:  2014-10       Impact factor: 5.934

10.  Indications and Efficacy of Gamma Knife Stereotactic Radiosurgery for Recurrent Glioblastoma: 2 Decades of Institutional Experience.

Authors:  Brandon S Imber; Ishan Kanungo; Steve Braunstein; Igor J Barani; Shannon E Fogh; Jean L Nakamura; Mitchel S Berger; Edward F Chang; Annette M Molinaro; Juan R Cabrera; Michael W McDermott; Penny K Sneed; Manish K Aghi
Journal:  Neurosurgery       Date:  2017-01-01       Impact factor: 4.654

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.